We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App

Seegene Allplex 2019-nCoV Assay (SARS-CoV-2) Granted Expanded FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 31 Jul 2020
Print article
Image: Allplex 2019-nCoV Assay (Photo courtesy of Seegene, Inc.)
Image: Allplex 2019-nCoV Assay (Photo courtesy of Seegene, Inc.)
Seegene, Inc. (Seoul, South Korea) has been granted expanded Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its Allplex 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 disease.

Seegene's Allplex 2019-nCoV Assay, which had initially received EUA on April 21, 2020, has a unique feature that identifies three different target genes (E, RdRP and N genes) simultaneously in a single reaction tube/well, which allows for highly accurate results and maximizes the throughput for high volume testing. The current expansion greatly increases the number of nucleic acid extraction/isolation systems and extraction kits as well as PCR instruments. Laboratories can now utilize Seegene STARlet, Seegene NIMBUS, Microlab STARlet IVD and Microlab NIMBUS IVD all with Seegene STARMag RNA/DNA extraction kits, AdvanSure E3 System with AdvanSure NA EX Kits, GeneAll Ribospin vRD (Viral RNA/DNA Extraction Kit) (all six available through Seegene Technologies in San Francisco Bay Area), QIAamp DSP Viral RNA Mini kits, MagNA Pure 96 System, KingFisher Flex System with MagMAX Viral/Pathogen Nucleic Acid Isolation Kits. For PCR instruments, laboratories can use Bio-Rad CFX96 and CFX96 Touch systems or Applied Biosystems 7500 and 7500 Fast Dx real-time PCR detection systems.

"As COVID 19 pandemic continues, there is a continuous demand on increasing test capacity. We hope that the EUA expansion with more options will help laboratories choose the best-fit solution for additional test capacity. We continue to put our effort in ramping up the production as well as exploring new partnership to offer more solution to the market. Our goal is to provide a very affordable and scalable testing solution for both large and small laboratories anywhere in the US," said Dr. Jong-Yoon Chun, CEO of Seegene.

Print article


Molecular Diagnostics

view channel
Image: The NovaSeq 6000 Sequencing System offers high-throughput sequencing across a broad range of applications (Photo courtesy of Illumina).

Somatic Evolution Identified in Non-Neoplastic IBD-Affected Colon

Inflammatory bowel disease (IBD) is a debilitating disease characterized by repeated flares of intestinal inflammation. The two major subtypes of IBD, Crohn’s disease (CD) and ulcerative colitis (UC) are... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.